Abstract
Despite the progress in the development of new anticancer strategies, cancer is rapidly spreading around the world and remains one of the most common diseases. For more than 40 years, doxorubicin has been widely used in the treatment of solid and hematological tumors. At the same time, the problem of its cardiotoxicity remains unresolved, despite the high efficiency of this drug. Symptomatic therapy is used as a treatment for side-effects of doxorubicin or pathological conditions that have already appeared in their background. To date, there are no treatment methods for doxorubicin cardiomyopathy as such. A drug such as nicotinamide riboside can play an important role in solving this problem. Nicotinamide riboside is a pyridine nucleoside similar to vitamin B3 that acts as a precursor to NAD+. There is no published research on nicotinamide riboside effects on cardiomyopathy, despite the abundance of works devoted to the mechanisms of its effects in various pathologies. The review analyzes information about the effects of nicotinamide riboside on various experimental models of pathologies, its role in the synthesis of NAD+, and also considers the possibility and prospects of its use for the prevention of doxorubicin cardiomyopathy.
Highlights
According to the World Health Organization, cancer is one of the leading causes of death worldwide
Shimada et al showed that SIRT1 promotes the expression of manganese superoxide dismutase (MnSOD) and increases resistance to oxidative stress in endothelial cells of human retinal microvessels [90]
This study showed that Nicotinamide riboside (NR) administration increased NAD+ levels and decreased heart damage and myocardial dysfunction in chemically-treated mice
Summary
According to the World Health Organization, cancer is one of the leading causes of death worldwide. Oncological diseases at late stages are detected in patients in the overwhelming majority of cases. This necessitates chemotherapy as part of a combined therapy and as an independent form of treatment. The development of approaches aimed at preventing doxorubicin cardiomyopathy remains relevant. In solving this problem, drugs based on NAD+. Over the past 10 years, the number of studies devoted to the characteristics of the metabolism of NAD+ has increased. This is due to the discovery of nicotinamide riboside kinases. NAD+ , and considers the possibility and prospects of its use for the prevention of doxorubicin cardiomyopathy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
